Back HIV/HCV Coinfection

HIV/HCV Coinfection

EASL 2014: Sofosbuvir + Ledipasvir Produces Early Cure for 100% of HIV/HCV Coinfected Patients

Treatment for 12 weeks with a coformulation of sofosbuvir plus ledipasvir led to sustained response for all HIV/HCV coinfected individuals with genotype 1 hepatitis C followed for 12 weeks post-treatment, according to interim findings from the ERADICATE study presented at the 49thEASL International Liver Congress (EASL 2014) this week in London.

alt

Read more:

Hepatitis C Liver Decompensation Remains a Problem for People with HIV Despite Good ART

People with HIV who are coinfected with hepatitis C virus (HCV) continue to have a higher risk for decompensated cirrhosis, or liver failure, even in the era of effective antiretroviral therapy (ART), according to a study published in the March 18 Annals of Internal Medicine. As such, they especially stand to benefit from new interferon-free hepatitis C treatments.

alt

Read more:

AASLD 2013: Faldaprevir + Interferon/Ribavirin Leads to Early Sustained Response for HIV/HCV Coinfected

The HCV protease inhibitor faldaprevir plus pegylated interferon and ribavirin improved 4-week sustained response rates for HIV positive people coinfected with genotype 1 hepatitis C in the STARTVerso4 trial, according to a poster presented at the 64th AASLD Liver Meeting last week in Washington, DC.

alt

Read more:

Coverage of the 2014 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014), March 3-6, 2014, in Boston.

Conference highlights include new treatments for hepatitis C, HIV experimental therapies and treatment strategies, HIV cure research, HIV-related conditions, treatment as prevention and PrEP, and HIV/HCV coinfection.

Full listing by topic

Selected presentations and slide webcasts 

3/9/14

alt

AASLD 2013: Sofosbuvir + Ribavirin Produces Sustained Response in 76% of GT 1 HIV/HCV Coinfected Patients

An interferon-free regimen of sofosbuvir plus ribavirin taken for 24 weeks cured three-quarters of previously untreated HIV positive people coinfected with hepatitis C virus (HCV) genotype 1, while 12 weeks of treatment cured 88% and 67% of those with genotypes 2 or 3, according to findings from the Phase 3 PHOTON-1 study presented this week at the 64th AASLD Liver Meeting in Washington, DC.

alt

Read more:

Coverage of the 2014 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 21st Conference on Retroviruses and Opportunistic infections (CROI 2014), March 3-6, 2014, in Boston.

Conference highlights include new treatments for hepatitis C, HIV experimental therapies and treatment strategies, HIV cure research, HIV-related conditions, treatment as prevention and PrEP, and HIV/HCV coinfection.

Full HIVandHepatitis.com coverage by topic

Selected presentations and slide webcasts 

3/9/14

alt

AASLD 2013: High Response Rates with Telaprevir Triple Therapy for HIV+ Men with Acute Hepatitis C

Adding telaprevir (Incivek) to pegylated interferon and ribavirin shortens the duration of treatment and improves sustained response rates for HIV positive men with acute hepatitis C virus (HCV) infection, according to a presentation yesterday at the at the 64thAASLD Liver Meeting in Washington, DC.

alt

Read more:

CROI 2014: Retrovirus Conference Now Underway in Boston

The 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) kicked off in Boston this week with a program for young investigators, a press conference on new hepatitis C treatments, and opening lectures on HIV immune response and cross-species transmission and an update on the epidemic in West Africa.

HIVandHepatitis.com will be on site all week bringing you the latest news.alt

Read more:

AASLD Liver Meeting Starts this Weekend in Washington, DC

The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting gets underway this Friday, running November 1-5 at the Walter E. Washington Convention Center in Washington, DC. The highlight of this year's meeting will be numerous presentations on next-generation direct-acting antivirals (DAAs) for hepatitis C, now in late stages of development, both as interferon add-ons and in interferon-free regimens.

alt

Read more:

CROI 2014: The Role of Interferon in HIV Response [VIDEO]

Although interferon is on its way out as a standard of care for hepatitis C, researchers are learning more about its role in HIV, conference vice chair Julie Overbaugh said at a media briefing on the opening day of the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt

Read more:

Coverage of the 2013 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013) in Boston, November 1-5, 2013.

Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.

Full listing by topic

10/30/13

alt

CROI 2014: Retrovirus Conference Starts Monday in Boston

The 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) will take place next week, March 3-6, at the Hynes Convention Center in Boston. HIVandHepatitis.com will be on site all week to bring you the latest news coverage about HIV, hepatitis C, and related topics.

alt

Read more:

EACS 2013: Faldaprevir Demonstrates Good Early Response in Genotype 1 HIV/HCV Coinfection

The HCV protease inhibitor faldaprevir added to pegylated interferon and ribavirin increased the likelihood that HIV/HCV co-infected people would achieve a sustained response at 4 weeks after completing treatment, according to a report at the 4th European AIDS Conference last week in Brussels.

alt

Read more:

Antiretroviral Therapy Reduces Liver Decompensation Risk in HIV/HCV Coinfected Patients

HIV positive people with hepatitis C coinfection who start combination antiretroviral therapy (ART) are less likely to develop decompensated liver disease, or liver failure, according to a study published in the March 1, 2014, edition of Clinical Infectious Diseases. These findings offer further support for early ART initiation for people with viral hepatitis.

alt

Read more:

Coverage of the 14th European AIDS Conference

HIVandHepatitis.com coverage of the 14th European AIDS Conference, sponsored by the European AIDS Clinical Society (EACS), October 16-19, 2013, in Brussels.

Conference highlights include antiretroviral therapy strategies and new HIV drugs, new treatment for hepatitis C, biomedical HIV prevention, HIV cure research, and the epidemic in Eastern Europe.

Full listing by topic

10/20/13

alt

 

 

Highlights from 2013 ICAAC, IDWeek, and EACS Meetings

Latest Positive Pulse Newsletter

In this overview Paul Sax from Harvard Medical School and Mark Sulkowski from Johns Hopkins discuss selected highlights from this fall's Interscience Conference on Microbial Agents and Chemotherapy (ICAAC), IDWeek, and the European AIDS Conference. The newsletter is available to all for free, with continuing medical education (CME) credit available for physicians and nurses.alt

Read more:

European AIDS Conference Features Latest HIV & Hepatitis C Data, New Guidelines

The European AIDS Conference, the biennial meeting of the European AIDS Clinical Society (EACS), opened Wednesday in Brussels, the site of the organization's first meeting 25 years ago. The conference included the latest news on antiretroviral therapy (ART) for HIV, hepatitis C treatment for HIV/HCV coinfected people, and biomedical HIV prevention, as well as the launch of updated European treatment guidelines.

alt

Read more:

Antiretrovirals Reduce Liver Decompensation in HIV/HCV Coinfected

Starting antiretroviral therapy (ART) reduces the likelihood that HIV positive people coinfected with hepatitis C virus (HCV) will develop decompensated liver disease, according to a report published in the November 27, 2013, advance edition of Clinical Infectious Diseases.

alt

Read more:

IDWeek 2103: Predicting Response to Acute Hepatitis C Treatment for HIV/HCV Coinfected People

HIV/HCV coinfected people with higher HCV viral load, lower CD4 T-cell counts, older age, and unfavorable IL28B status may not respond as well to interferon-based treatment for acute hepatitis C and may benefit from adding a direct-acting antiviral agent, researchers reported at the 2nd IDWeek meeting last week in San Francisco.

alt

Read more:

HIVandHepatitis.com Complete 2013 Conference Coverage

HIVandHepatitis.com 2013 conference and meeting coverage.

Full conference listing

12/30/13

alt

 

 

IDWeek 2013: Liver Fibrosis Linked to Immune Activation in HIV/HCV Coinfected Women

CD4 and CD8 T-cell activation were found to be associated with biomarkers of liver fibrosis among HIV/HCV coinfected women, suggesting that immune activation related to persistent HIV infection may play a role in liver disease progression, researchers reported at the Second IDWeek conference this week in San Francisco.

alt

Read more: